Advertisement
Advertisement
U.S. Markets open in 13 mins
S&P Futures
4,010.50 -9.25 (-0.23%) Dow Futures
32,095.00 -25.00 (-0.08%) Nasdaq Futures
12,353.25 -29.50 (-0.24%) Russell 2000 Futures
1,786.00 -3.50 (-0.20%) Crude Oil
110.25 -0.24 (-0.22%) Gold
1,807.30 -0.90 (-0.05%)
Marinus Pharmaceuticals, Inc. (MRNS)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-Market:
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 4.86 |
| Open | 5.30 |
| Bid | 5.00 x 1100 |
| Ask | 6.29 x 800 |
| Day's Range | 5.05 - 5.80 |
| 52 Week Range | 4.19 - 19.83 |
| Volume | |
| Avg. Volume | 399,095 |
| Market Cap | 208.124M |
| Beta (5Y Monthly) | 1.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.48 |
| Earnings Date | Mar 07, 2022 - Mar 11, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.89 |
- Zacks
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue Estimates
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 40.23% and 548.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
RADNOR, Pa., May 12, 2022--Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
- Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
RADNOR, Pa., May 10, 2022--Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
